Metraipolis › archive › dc_2df0788593d3
High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020-July 2021 — Europe PMC PMID:38923981
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/38923981
- DOI
- 10.1371/journal.pone.0305129
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-06T17:10:50.390Z
- SHA-256 of the archived text
906b57870e70afffbd43006396d5942e16cbe5a7539744333f610f8d7c0e46b7- Stable URL of this page
https://metraipolis.com/documento/dc_2df0788593d3
How to cite
High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020-July 2021 — Europe PMC PMID:38923981 — Europe PMC (en), https://europepmc.org/article/MED/38923981 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_2df0788593d3 (Metraipolis archive dc_2df0788593d3, sha256 906b57870e70afffbd43006396d5942e16cbe5a7539744333f610f8d7c0e46b7)
BibTeX
@misc{dc2df0788593d3,
title = {High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020-July 2021 — Europe PMC PMID:38923981},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/38923981},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_2df0788593d3; sha256 906b57870e70afffbd43006396d5942e16cbe5a7539744333f610f8d7c0e46b7},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/38923981. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Background: In 2019, WHO recommended dolutegravir (DTG) as a backbone for first- and second-line antiretroviral therapy (ART) regimens for people living with HIV (PLHIV). According to the 2018 Uganda's HIV treatment guidelines, patients with viral non-suppression (≥1,000 copies/mL) should receive intensive adherence counseling (IAC) with repeat viral load (VL) within 6 months. This analysis focused on the prevalence and factors associated with viral suppression following IAC among PLHIV on DTG-based regimens (DBRs) with an initial episode of viral non-suppression (VNS) in Uganda. Methods: We conducted a retrospective analysis for PLHIV on DBRs with an initial episode of VNS (≥1,000 copies/mL) in Uganda during October 2019-September 2020 who had a follow up VL test result during September 2020-July 2021. Data were abstracted from the Central Public Health Laboratory (CPHL) database, including patient demographics and VL results. Viral non-suppression (VNS) was defined as a VL test result of ≥1,000 copies/mL. We characterized PLHIV on DBRs and used logistic regression models to determine factors associated with VL suppression after an initial episode of VNS. Results: A total of 564 PLHIV on DBRs with an initial episode of VNS were followed up and 43 were excluded due to missing data. Of the 521, 220 (42.2%) were children (<15 years) and 231 (44.3%) were female. Median age was 28 years (interquartile range [IQR]: 12-43 years), and median duration on DBRs was 12 months (IQR: 6-15 months). Overall, 80.8% (421/521) PLHIV had a suppressed viral load at first follow up testing (children = 74.5% [164/220]; adults = 85.4% [257/301]). Children with initial VL results ≥5,000 copies/mL were less likely to achieve viral suppression at follow up testing compared to those with <5,000 copies/mL (AOR: 0.38; 95% CI: 0.20-0.71; p = 0.002). Conclusions: In a programmatic setting, most adults and children suppressed following an initial episode of VNS on DBRs. High rates of suppression after VNS suggest adherence challenges, rather than drug resistance. Continuation of DBRs should be considered before regimen switch. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2024 (prima pubblicazione 2024-06-26). Identificativi: PMID 38923981 · PMCID PMC11206940 · DOI 10.1371/journal.pone.0305129. Descrittori MeSH principali: HIV Infections; Oxazines; Piperazines; Pyridones; Heterocyclic Compounds, 3-Ring; Viral Load. Pagina: https://europepmc.org/article/MED/38923981 — https://doi.org/10.1371/journal.pone.0305129. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-06T15:36:03.061Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.